About Peptidyl-prolyl cis-trans isomerase E
Peptidyl-prolyl cis-trans isomerase E (PPIE) is a protein
from Homo sapiens identified by UniProt accession
Q9UNP9, 301 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | Peptidyl-prolyl cis-trans isomerase E |
| UniProt accession | Q9UNP9 |
| Gene | PPIE |
| Organism | Homo sapiens |
| Length | 301 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (48)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.16
- heel bone mineral density · score 0.15
- peptidyl-prolyl cis-trans isomerase E measurement · score 0.13
- diabetes mellitus · score 0.08
- hemoglobin E-beta-thalassemia syndrome · score 0.06
- Adult-onset autosomal recessive sideroblastic anemia · score 0.05
- hemoglobin D disease · score 0.05
- hemochromatosis type 5 · score 0.05
- FTH1-related iron overload · score 0.05
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UNP9-F1 | alphafold | PREDICTED | 83.20 | — |
Amino-acid sequence (301 residues)
MATTKRVLYV GGLAEEVDDK VLHAAFIPFG DITDIQIPLD YETEKHRGFA FVEFELAEDA AAAIDNMNES ELFGRTIRVN LAKPMRIKEG SSRPVWSDDD WLKKFSGKTL EENKEEEGSE PPKAETQEGE PIAKKARSNP QVYMDIKIGN KPAGRIQMLL RSDVVPMTAE NFRCLCTHEK GFGFKGSSFH RIIPQFMCQG GDFTNHNGTG GKSIYGKKFD DENFILKHTG PGLLSMANSG PNTNGSQFFL TCDKTDWLDG KHVVFGEVTE GLDVLRQIEA QGSKDGKPKQ KVIIADCGEY V
Explore Peptidyl-prolyl cis-trans isomerase E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets